U.S., June 2 -- ClinicalTrials.gov registry received information related to the study (NCT07617012) titled 'The Safety, Tolerability, and Efficacy of Dopaminergic Neural Progenitor Cells (XS411CN Cell Injection) for the Treatment of Multiple System Atrophy Parkinsonian Variant (MSA-P).' on May 18.
Brief Summary: A Phase I Study to Assess the Safety, Tolerability and Efficacy of dopaminergic neural progenitor cells (XS411CN cell injection) for the treatment of multiple system atrophy Parkinsonian variant (MSA-P).
Study Start Date: June 15
Study Type: INTERVENTIONAL
Condition:
the Treatment of Multiple System Atrophy Parkinsonian Variant (MSA-P)
Intervention:
DRUG: XS411CN Cell Injection
Injection, 5.0x10^6 cells, once, 12 months
Rec...